1. Medtech Insight
  2. >>Archive

Medtech: Assessing Potential Return On Investment

Medtech entrepreneurs and investors are awakening to a new reality in venture funding, where exit times are lengthening and returns on investment are falling short. At the recent IN3 meeting in Dublin, a panel of medtech investors discussed how they are adapting their investment strategies to this changing landscape.

With the flow of medtech investment money continuing to shift from early- to late-stage financings, a new reality is emerging for start-ups and the VCs investing in these companies.

For one thing, a US versus EU divide is becoming more apparent: while more VCs in the US are turning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Zimmer Biomet Readies Iodine-Coated Hip For 2025 Japan Launch, Plans To Expand Platform To New Joint

 
• By Shubham Singh

Zimmer Biomet is preparing to introduce iodine-coated hip implants to international markets, offering joint replacement patients a new alternative intended to ward off infection. The company intends to broaden the platform’s reach into “knees, shoulders and other categories in due time.”

From Risk Aversion to Real-World Impact: How Medtech Firms Can Harness AI

 
• By Elizabeth Orr

Medical device companies are increasingly using AI to improve regulatory affairs strategies but face barriers such as risk aversion, regulatory clarity and data governance issues. Experts suggest a design control approach and human oversight to ensure successful AI integration.

Hundreds Of Adverse Events, Multiple Deaths, Associated With Abbott Correction Of Libre 3 Sensors

 
• By Brian Bossetta

Abbott has initiated a medical device correction for about 3 million FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors in the US after internal testing detected a risk the device may produce inaccurate glucose readings.